Nabriva Therapeutics plc Annual Operating Income (Loss) in USD from 2014 to 2022

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Nabriva Therapeutics plc quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2022.
  • Nabriva Therapeutics plc Operating Income (Loss) for the quarter ending June 30, 2023 was -$12M, a 15.6% decline year-over-year.
  • Nabriva Therapeutics plc Operating Income (Loss) for the twelve months ending June 30, 2023 was -$54M, a 18.3% decline year-over-year.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2022 was -$55.5M, a 14.3% decline from 2021.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2021 was -$48.5M, a 26.6% increase from 2020.
  • Nabriva Therapeutics plc annual Operating Income (Loss) for 2020 was -$66.1M, a 16.8% increase from 2019.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2022 -$55.5M -$6.96M -14.3% Jan 1, 2022 Dec 31, 2022 10-K 2023-04-17
2021 -$48.5M +$17.6M +26.6% Jan 1, 2021 Dec 31, 2021 10-K 2023-04-17
2020 -$66.1M +$13.4M +16.8% Jan 1, 2020 Dec 31, 2020 10-K 2023-04-17
2019 -$79.5M +$34.9M +30.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-29
2018 -$114M -$40.6M -55% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-11
2017 -$73.8M -$18.7M -34% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 -$55M -$27.3M -98.3% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-12
2015 -$27.8M -$17.1M -160% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-16
2014 -$10.7M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.